BGI SENTISTM Cancer+Discovery
The Power Of Knowing
BGI’s Cancer + Discovery Panel (BGI C + D Panel) provides one of the most comprehensive and accurate Next Generation Sequencing (NGS) solution for the identification of
Clinically actionable mutations (somatic & genetic variants)
TMB and MSI status
Discovery of novel variants (with important functions in cancer)
Drug sensitivity /toxicity
Whole Exon Coverage
Major genetic alterations
FDA & NCCN guideline drug recommendation
Why choose us?
Comprehensive
Robust
Affordable
For more information on BGI’s Cancer+ Discovery Test :
Please refer https://www.bgi.com/global/molecular-genetics/sentis-oncology/bgi-sentis-cancer-discovery-panel/ or
Contact your local sales representative or Email us at info@sayretherapeutics.com